title: Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.
abstract: METHODS
  Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for peripheral artery disease (PAD).
  
  
  METHODS
  The USPSTF reviewed the evidence on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a risk predictor for cardiovascular disease (CVD). The review focused on resting ABI as the sole screening method; the diagnostic performance of ABI testing in primary care populations, unselected populations, and asymptomatic populations; the predictive value of ABI testing for major CVD outcomes in primary care or unselected populations; and the effect of treatment on general CVD and PAD-specific morbidity in patients with asymptomatic or minimally symptomatic PAD.
  
  
  METHODS
  This recommendation applies to asymptomatic adults who do not have a known diagnosis of PAD, CVD, severe chronic kidney disease, or diabetes.
  
  
  CONCLUSIONS
  The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for PAD and CVD risk assessment with the ABI in adults. (I statement).
authors.forename: Virginia A
authors.initials: VA
authors.lastname: Moyer
mesh_terms: D000328:Adult; D055109:Ankle Brachial Index; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D058070:Asymptomatic Diseases; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D017281:Cost of Illness; D042241:Early Diagnosis; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008403:Mass Screening / Q000009:adverse effects / Q000379:methods*; D058729:Peripheral Arterial Disease / Q000175:diagnosis* / Q000188:drug therapy; D011237:Predictive Value of Tests; D018570:Risk Assessment
chemical_list: D005343:Fibrinolytic Agents; D001241:Aspirin